e-learning
resources
ERJ
2011
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response
Dijkstra A., Postma D.S., Bruinenberg M., van Diemen C.C., Boezen H.M., Koppelman G.H., Timens W., Vonk J.M.
Source:
Eur Respir J 2011; 38: 1036-1043
Journal Issue:
November
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dijkstra A., Postma D.S., Bruinenberg M., van Diemen C.C., Boezen H.M., Koppelman G.H., Timens W., Vonk J.M.. SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response. Eur Respir J 2011; 38: 1036-1043
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
Source: Eur Respir J 2016; 47:1568-1571
Year: 2016
Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
E-cadherin gene polymorphisms in asthma patients using inhaled corticosteroids
Source: Eur Respir J 2011; 38: 1044-1052
Year: 2011
Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model
Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung
Year: 2010
The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis
Source: International Congress 2017 – Systemic and airway biomarkers
Year: 2017
Association of VEGF polymorphisms with childhood asthma, lung function and airway responsiveness
Source: Eur Respir J 2009; 33: 1287-1294
Year: 2009
Platelet activating factor receptor (PAFr) expression is increased in airways of COPD patients but is not attenuated by inhaled corticosteroid (ICS)
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
E-cadherin (
CDH-1
) polymorphisms associate with airway remodeling, inflammation and FEV
1
decline in asthma patients using inhaled corticosteroids (ICS)
Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases
Year: 2010
Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017
ADRB2 Gly16Arg polymorphism, asthma control and lung function decline
Source: Eur Respir J 2011; 38: 1029-1035
Year: 2011
The role of glucocorticoid receptor a and ß isoforms in exacerbations of asthma, COPD, and ACOS
Source: International Congress 2017 – Gene signatures in bronchial diseases
Year: 2017
The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005
Increased expression of ADRB2, CHRM3 and glucocorticoid alpha receptor genes in blood leukocytes of COPD patients
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
GLCCI1
variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids
Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD
Year: 2014
ADRB2R gene polymorphism (pol.) associated with the severity of cystic fibrosis(CF) and the effectiveness of the use of inhaled bronchodilator
Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies
Year: 2010
Association of genetic variations of CC chemokine receptor-2 (CCR2) with atopic asthma, but not with nonatopic asthma
Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology
Year: 2005
Monitoring asthma and adjusting the inhaled steroid dose: is there a better way?
Source: Annual Congress 2005 - Are we ready for "inflammometry"? The role of eNO in asthma management
Year: 2005
The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD
Source: International Congress 2018 – New predictors of morbidity and mortality in COPD
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept